Data Presented at the International Diabetes Federation World Congress Compares JANUMET (sitagliptin/metformin HCl) to Metformin Alone as Initial Therapy

New data presented at the 20th World Diabetes Congress of the International Diabetes Federation (IDF) compared two strategies for the initiation of treatment for patients with type 2 diabetes. In the first phase (18 weeks), the treatment effects of JANUMET (a fixed-dose combination of sitagliptin and metformin) and metformin as initial therapy were compared. In the second phase (26 weeks), the treatment strategies of initiating JANUMET versus initiating metformin were compared (investigators used their clinical discretion, based upon glucose and A1C values, to add other diabetes treatments to the initially assigned treatment regimen when necessary to achieve blood sugar control). At the...

Want to see the full article?

• Purchase this article for only $3.00